129 related articles for article (PubMed ID: 27591155)
1. Factors related to completeness of medical abortion with mifepristone and misoprostol.
Jiang WX; He FF; Shen Q; Tao XJ; Zhao CC; Shen ZJ; Zhu XQ
J Chin Med Assoc; 2017 Feb; 80(2):96-102. PubMed ID: 27591155
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor mRNA and its protein expression in decidua after terminating early pregnancy by mifepristone plus misoprostol.
Huang L; Shi Y
Chin Med J (Engl); 2001 May; 114(5):517-9. PubMed ID: 11780417
[TBL] [Abstract][Full Text] [Related]
3. Elevated mRNA expression of PGF2α receptor splice variant 2(FP-V2) in human decidua is associated with incomplete mifepristone-misoprostol-induced early medical abortion by regulation of interleukin-8.
Ma C; Feng W; Han W; Lu Y; Liu W; Sui Y; Zhao N; Lye SJ; Li J
J Matern Fetal Neonatal Med; 2016 Nov; 29(21):3472-7. PubMed ID: 26744271
[TBL] [Abstract][Full Text] [Related]
4. Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol.
Song LP; Tang SY; Li CL; Zhou LJ; Mo XT
J Obstet Gynaecol Res; 2018 Sep; 44(9):1705-1711. PubMed ID: 29974571
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City.
Sanhueza Smith P; Peña M; Dzuba IG; García Martinez ML; Aranguré Peraza AG; Bousiéguez M; Shochet T; Winikoff B
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):75-82. PubMed ID: 25702071
[TBL] [Abstract][Full Text] [Related]
6. Elevated expression levels of matrix metalloproteinase-9 in placental villi and tissue inhibitor of metalloproteinase-2 in decidua are associated with prolonged bleeding after mifepristone-misoprostol medical abortion.
Zhuang Y; Qian Z; Huang L
Fertil Steril; 2014 Jan; 101(1):166-171.e2. PubMed ID: 24210229
[TBL] [Abstract][Full Text] [Related]
7. Monitoring medical abortion using mifepristone/misoprostol combination with ultrasonogram and serum human chorionic gonadotropin.
Chou SY; Chen CY; Chiang HK; Chow PK; Wang CC; Hsu CS
Taiwan J Obstet Gynecol; 2006 Mar; 45(1):48-52. PubMed ID: 17272208
[TBL] [Abstract][Full Text] [Related]
8. Tissue-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA and their protein expression levels in human decidua after early pregnancy termination by mifepristone plus misoprostol.
Huang L; Shi Y
Chin Med J (Engl); 2001 Jun; 114(6):628-31. PubMed ID: 11780441
[TBL] [Abstract][Full Text] [Related]
9. Comparison or oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion.
Mittal S; Agarwal S; Kumar S; Batra A
Indian J Med Res; 2005 Aug; 122(2):132-6. PubMed ID: 16177470
[TBL] [Abstract][Full Text] [Related]
10. Current medical abortion care.
Creinin MD
Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone and misoprostol is safe and effective method in the second-trimester pregnancy termination.
Nissi R; Santala M; Immonen E; Talvensaari-Mattila A
Arch Gynecol Obstet; 2016 Nov; 294(6):1243-1247. PubMed ID: 27522599
[TBL] [Abstract][Full Text] [Related]
12. [Expression of T-lymphocytes and cytokines in the decidua of mifepristone with misoprostol for terminating early pregnancy].
Lu S; Wu R; Wang Z
Zhonghua Fu Chan Ke Za Zhi; 2001 Oct; 36(10):625-7. PubMed ID: 16134529
[TBL] [Abstract][Full Text] [Related]
13. Ovulation resumption after medical abortion with mifepristone and misoprostol.
Schreiber CA; Sober S; Ratcliffe S; Creinin MD
Contraception; 2011 Sep; 84(3):230-3. PubMed ID: 21843685
[TBL] [Abstract][Full Text] [Related]
14. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
[TBL] [Abstract][Full Text] [Related]
15. Medical abortion with mifepristone and misoprostol: a clinical trial in Taiwanese women.
Tsai EM; Yang CH; Lee JN
J Formos Med Assoc; 2002 Apr; 101(4):277-82. PubMed ID: 12101864
[TBL] [Abstract][Full Text] [Related]
16. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
Dahiya K; Ahuja K; Dhingra A; Duhan N; Nanda S
Arch Gynecol Obstet; 2012 Apr; 285(4):1055-8. PubMed ID: 22009509
[TBL] [Abstract][Full Text] [Related]
18. Timing and indication for curettage after medical abortion in early pregnant women with prior uterine incision.
Wang G; Li D; Manconi F; Dong B; Zhang Y; Sun B
Contraception; 2010 Jan; 81(1):62-6. PubMed ID: 20004275
[TBL] [Abstract][Full Text] [Related]
19. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.
von Hertzen H; Piaggio G; Wojdyla D; Marions L; My Huong NT; Tang OS; Fang AH; Wu SC; Kalmar L; Mittal S; Erdenetungalag R; Horga M; Pretnar-Darovec A; Kapamadzija A; Dickson K; Anh ND; Tai NV; Tuyet HT; Peregoudov A;
BJOG; 2009 Feb; 116(3):381-9. PubMed ID: 19187370
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasi-randomized controlled trial.
Chawdhary R; Rana A; Pradhan N
J Obstet Gynaecol Res; 2009 Feb; 35(1):78-85. PubMed ID: 19215552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
